Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study
Authors:
- Shuell De SouzaSSShuell De Souza
- Jeffrey Kahol de JongJJJeffrey Kahol de Jong
- Ylenia PeroneYPYlenia Perone
- Shishir ShettySSShishir Shetty
- Maria QurashiMQMaria Qurashi
- Mathew VithayathilMVMathew Vithayathil
- Tahir ShahTSTahir Shah
- Paul RossPRPaul Ross
- Laura TemperleyLTLaura Temperley
- Vincent S. YipVYVincent S. Yip
- Abhirup BanerjeeABAbhirup Banerjee
- Dominik BettingerDBDominik Bettinger
Open Access
Abstract
Introduction: The COVID-19 pandemic has caused severe disruption of healthcare services worldwide and interrupted patients’ access to essential services. During the first lockdown, many healthcare services were shut to all but emergencies. In this study, we aimed to determine the immediate and long-term indirect impact of COVID-19 health services utilisation on hepatocellular cancer (HCC) outcomes. Methods: A prospective cohort study was conducted from 1 March 2020 until 30 June 2020, correlating to the first wave of the COVID-19 pandemic. Patients were enrolled from tertiary hospitals in the UK and Germany with dedicated HCC management services. All patients with current or past HCC who were discussed at a multidisciplinary meeting (MDM) were identified. Any delay to treatment (DTT) and the effect on survival at one year were reported. Results: The median time to receipt of therapy following MDM discussion was 49 days. Patients with Barcelona Clinic Liver Cancer (BCLC) stages-A/B disease were more likely to experience DTT. Significant delays across all treatments for HCC were observed, but delay was most marked for those undergoing curative therapies. Even though severe delays were observed in curative HCC treatments, this did not translate into reduced survival in patients. Conclusion: Interruption of routine healthcare services because of the COVID-19 pandemic caused severe delays in HCC treatment. However, DTT did not translate to reduced survival. Longer follow is important given the delay in therapy in those receiving curative therapy.Keywords
All Related Versions
Funding Information
- Bayer HealthCare
This publication has 25 references indexed in Scilit:
- Management of Hepatocellular Cancer in the time of SARS-CoV-2Liver International, 2020
- Poor clinical outcomes for patients with cancer during the COVID-19 pandemicThe Lancet Oncology, 2020
- Evidence mounts on the disproportionate effect of COVID-19 on ethnic minoritiesThe Lancet Respiratory Medicine, 2020
- The impact of the COVID-19 pandemic on cancer careNature Cancer, 2020
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methodsInternational Journal of Cancer, 2018
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2016
- Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal CancerJAMA, 2011
- Intergenerational continuities of ethnic inequalities in general health in EnglandJournal of Epidemiology and Community Health, 2008
- The relationship between waiting time for radiotherapy and clinical outcomes: A systematic review of the literatureRadiotherapy and Oncology, 2008